构建国家基本药物目录适时调整管理机制的必要性与可行性研究

李颖; 隋艾蓉; 任鸣睿; 邵蓉; 颜建周

doi:10.13748/j.cnki.issn1007-7693.20250453

构建国家基本药物目录适时调整管理机制的必要性与可行性研究

Study on Necessity and Feasibility of Timely Adjustment Management of Essential Medicine List in China

摘要

摘要:
目的研究中国基本药物目录适时调整的必要性和可行性，提出完善中国国家基本药物目录动态调整机制的政策建议。
方法通过文献研究和描述性分析，从基本国情、药物研发新形势、指南调整周期变化3个维度分析必要性；从国内法律法规基础和国际经验2个维度分析可行性。
结果中国有必要建立基本药物目录适时调整机制，且具备法律法规依据和国际经验参考，具有可行性。
结论建议完善基本药物目录动态调整机制，建立“三年常规调整+一年适时调整”模式，同时制定配套政策，提升目录先进性和合理性，使其更贴近临床需求，更好发挥保障药品供应、促进合理用药和改善药品可及性的作用。

Abstract:
OBJECTIVE To study the necessity and feasibility of timely adjustments to China's essential medicine list, and propose policy recommendations for improving the dynamic adjustment mechanism.
METHODS Through literature research and descriptive analysis, the necessity was analyzed from 3 dimensions: the basic national conditions, the new situation of drug development, and the changes in the guideline adjustment cycle; feasibility was analyzed based on domestic regulations and international experience.
RESULTS It was necessary for China to establish a timely adjustment mechanism for the essential drug list, which had a legal and regulatory basis and international experience for reference, making it feasible.
CONCLUSION It is recommended to improve the dynamic adjustment mechanism by establishing a model of "three-year regular adjustments plus one-year timely adjustments", formulating supporting policies to enhance the advancement and rationality of the directory, making it more aligned with clinical needs, and better playing the role of ensuring drug supply, promoting rational drug use, and improving drug accessibility.

HTML全文

参考文献(25)

施引文献

资源附件(0)